Advances and challenges in the development and production of effective plant-based influenza vaccines

References

• Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Editors Fields Virology. 4th Edition. Lippincott, Williams & Wilkins; Philadelphia, USA; 2001. p. 1487-531
   Google Scholar
• Ruigrok RWH. Structure of influenza A, B and C viruses. In: Nicholson KG, Webster RG, Hay AJ, Editors Textbook of Influenza. Blackwell Science; Oxford, UK; 1998. p. 29-42
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza–United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010;59:1057-62
   PubMedGoogle Scholar
• World Health Organization. Influenza (Seasonal). Media Centre. Fact sheet №211. 2009. Available from: www.who.int/mediacentre/factsheets/fs211/en/index.html [Last accessed on 30 May 2014]
   Google Scholar
• Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197-201
   PubMed Web of Science ®Google Scholar
• Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15
   PubMed Web of Science ®Google Scholar
• Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-52
   PubMed Web of Science ®Google Scholar
• World Health Organization. D-G statement. 2009. Available from: www.who.int/mediacentre/news/statements/2009/h1n1pandemicphase620090611/en/index.html [Last accessed on 30 May 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Information on Avian Influenza. Available from: www.cdc.gov/flu/avianflu/index.htm [Last accessed on 30 May 2014]
   Google Scholar
• World Health Organization. Avian Influenza in Humans. Available from: www.who.int/influenza/human_animal_interface/avian_influenza/en/[Last accessed on 30 May 2014]
   Google Scholar
• World Health Organization. Cumulative Number of Confirmed Human Cases for Avian Influenza; A (H5N1) reported to WHO, 2003–2012. Available from: www.who.int/influenza/human_animal_interface/EN_GIP_20120607CumulativeNumberH5N1cases.pdf [Last accessed on 30 May 2014]
   Google Scholar
• Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-13
   PubMed Web of Science ®Google Scholar
• Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375:56-66
   PubMed Web of Science ®Google Scholar
• Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41-8
   PubMed Web of Science ®Google Scholar
• Keitel WA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I–II randomized clinical trial. J Infect Dis 2008;198:1309-16
   PubMed Web of Science ®Google Scholar
• Nolan TM, Richmond PC, Skeljo MV, et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008;26:4160.4167
   Google Scholar
• Matthews JT. Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge (Nat Acad Eng) 2006;36(3):17-24
   Google Scholar
• Schultz-Cherry S, Jones JC. Influenza vaccines: the good, the bad, and the eggs. Adv Virus Res 2010;77:63-84
   Google Scholar
• Michiels B, Govaerts F, Remmen R, et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011;29(49):9159-70
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(1):36-44
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014;9(3):e92153
   PubMed Web of Science ®Google Scholar
• Murray K. Application of recombinant DNA techniques in the development of viral vaccines. Vaccine 1988;6(2):164-74
   Google Scholar
• Pielak RM, Chou JJ. Influenza M2 proton channels. Biochim Biophys Acta 2011;1808(2):522-9
   PubMed Web of Science ®Google Scholar
• Noda T, Sagara H, Yen A, et al. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 2006;439:490-2
   PubMed Web of Science ®Google Scholar
• Gómez-Puertas P, Albo C, Pérez-Pastrana E, et al. Influenza virus matrix protein is the major driving force in virus budding. J Virol 2000;74(24):11538-47
   PubMed Web of Science ®Google Scholar
• Steinhauer DA, Wharton SA. Structure and function of the haemagglutinin. In: Nicholson KG, Webster RG, Hay AJ, Editors Textbook of Influenza. Blackwell Science; Oxford, UK; 1998. p. 54-64
   Google Scholar
• Colman PM. Structure and function of the neuraminidase. In: Nicholson KG, Webster RG, Hay AJ, Editors Textbook of Influenza. Blackwell Science; Oxford, UK; 1998. p. 65-73
   Google Scholar
• Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 1983;303:35-40
   PubMed Web of Science ®Google Scholar
• Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976;33:159-63
   PubMed Web of Science ®Google Scholar
• Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 1981;289:366-73
   PubMed Web of Science ®Google Scholar
• Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000;69:531-69
   PubMed Web of Science ®Google Scholar
• McCown MF, Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol 2005;79(6):3595-605
   PubMed Web of Science ®Google Scholar
• McCown MF, Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 2006;80(16):8178-89
   PubMedGoogle Scholar
• Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J Virol 2008;82(20):10059-70
   PubMed Web of Science ®Google Scholar
• Han T, Marasco WA. Structural basis of influenza virus neutralization. Ann N Y Acad Sci 2011;1217:178-90
   Google Scholar
• United States Food and Drug Administration. Guidance for Industry: clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. May 2007. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf [Last accessed on 30 May 2014]
   Google Scholar
• Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18(2):274-80
   PubMed Web of Science ®Google Scholar
• Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009;106(10):3877-82
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Madhun AS, Breakwell L, et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012;206(2):158-66
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176(10):6333-9
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309(1):13-17
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Ewen C, Zhou X, et al. Granzyme B: Correlates with protection and enhanced CTL. Vaccine 2009;27(18):2418-25
   PubMed Web of Science ®Google Scholar
• Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccin. Immunother 2013;9(2):405-8
   PubMed Web of Science ®Google Scholar
• Celik E, Calık P. Production of recombinant proteins by yeast cells. Biotechnol Adv 2012;30(5):1108-18
   PubMed Web of Science ®Google Scholar
• Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv 2012;30(5):1102-7
   PubMed Web of Science ®Google Scholar
• Drugmand JC, Schneider YJ, Agathos SN. Insect cells as factories for biomanufacturing. Biotechnol Adv 2012;30(5):1140-57
   Google Scholar
• Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012;30(5):1158-70
   PubMed Web of Science ®Google Scholar
• Jacobs PP, Callewaert N. N-glycosylation engineering of biopharmaceutical expression systems. Curr Mol Med 2009;9(7):774-800
   PubMed Web of Science ®Google Scholar
• Ellis RW, Gerety RJ. Key issues in the selection of an expression system for vaccine antigens. J Med Virol 1990;31(1):54-8
   Google Scholar
• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012;31(1):58-83
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004;72(11):6519-27
   PubMed Web of Science ®Google Scholar
• Tissot AC, Renhofa R, Schmitz N, et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010;5(3):e9809
   PubMed Web of Science ®Google Scholar
• Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008;10(1):56-61
   Google Scholar
• Athmaram TN, Saraswat S, Santhosh SR, et al. Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice. Virol J 2011;8:524
   PubMed Web of Science ®Google Scholar
• Murugan S, Ponsekaran S, Kannivel L, et al. Recombinant haemagglutinin protein of highly pathogenic avian influenza A (H5N1) virus expressed in Pichia pastoris elicits a neutralizing antibody response in mice. J. Virol. Meth 2013;187(1):20-5
   Google Scholar
• Wu CY, Yeh YC, Yang YC, et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 2010;5(3):e9784
   PubMed Web of Science ®Google Scholar
• Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002;20(Suppl 5):B17-23
   PubMed Web of Science ®Google Scholar
• Amorij JP, Huckriede A, Wilschut J, et al. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 2008;25(6):1256-73
   PubMed Web of Science ®Google Scholar
• Markham AP, Barrett BS, Esfandiary R, et al. Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine. J Pharm Sci 2010;99(11):4497-509
   Google Scholar
• Choudhari SP, Pendleton KP, Ramsey JD, et al. A systematic approach toward stabilization of CagL, a protein antigen from Helicobacter pylori that is a candidate subunit vaccine. J Pharm Sci 2013;102(8):2508-19
   Google Scholar
• Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009;27(4):449-67
   PubMed Web of Science ®Google Scholar
• Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010;8(5):620-37
   Google Scholar
• Mett V, Farrance CE, Green BJ, Yusibov V. Plants as biofactories. Biologicals 2008;36(6):354-8
   PubMed Web of Science ®Google Scholar
• Sharma AK, Sharma MK. Plants as bioreactors: recent developments and emerging opportunities. Biotechnol Adv 2009;27(6):811-32
   Google Scholar
• Matzke MA, Mette MF, Matzke AJ. Transgene silencing by the host genome defense: implications for the evolution of epigenetic control mechanisms in plants and vertebrates. Plant Mol Biol 2000;43(2-3):401-15
   PubMed Web of Science ®Google Scholar
• Verma D, Daniell H. Chloroplast vector systems for biotechnology applications. Plant Physiol 2007;145(4):1129-43
   PubMed Web of Science ®Google Scholar
• Daniell H, Singh ND, Mason H, Streatfield SJ. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 2009;14(12):669-79
   Google Scholar
• Streatfield SJ. Approaches to achieve high-level heterologous protein production in plants. Plant Biotechnol J 2007;5(1):2-15
   Google Scholar
• Yusibov V, Streatfield SJ, Kushnir N, et al. Hybrid viral vectors for vaccine and antibody production in plants. Curr Pharm Des 2013;19(31):5574-86
   PubMed Web of Science ®Google Scholar
• Lico C, Santi L, Twyman RM, et al. The use of plants for the production of therapeutic human peptides. Plant Cell Rep 2012;31(3):439-51
   PubMed Web of Science ®Google Scholar
• Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 2011;7:313-21
   PubMed Web of Science ®Google Scholar
• Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 2007;5:579-90
   PubMed Web of Science ®Google Scholar
• Mullard A. 2012;FDA drug approvals. Nat Rev Drug Discov 2013;12(2):87-90
   Google Scholar
• McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci USA 1999;96(2):703-8
   PubMed Web of Science ®Google Scholar
• McCormick AA, Reddy S, Reinl SJ, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci USA 2008;105(29):10131-6
   PubMed Web of Science ®Google Scholar
• D’Aoust MA, Lavoie PO, Couture MM, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008;6(9):930-40
   PubMed Web of Science ®Google Scholar
• D’Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010;8:607-19
   Google Scholar
• Gleba Y, Klimyuk V, Marillonnet S. Magnifection–a new platform for expressing recombinant vaccines in plants. Vaccine 2005;23(17-18):2042-8
   PubMed Web of Science ®Google Scholar
• Bendandi M, Marillonnet S, Kandzia R, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin’s lymphoma. Ann Oncol 2010;21:2420-7
   PubMed Web of Science ®Google Scholar
• Vezina L-P, D’Aoust MA, Landry N, et al. Plants as an Innovative and Accelerated Vaccine-Manufacturing Solution. BioPharm Inter Suppl 2011;25(5):s27-30
   Google Scholar
• Sainsbury F, Lomonossoff GP. Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant Physiol 2008;148(3):1212-18
   Google Scholar
• Musiychuk K, Stephenson N, Bi H, et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Respir Viruses 2007;1:19-25
   PubMed Web of Science ®Google Scholar
• Chichester JA, Musiychuk K, de la Rosa P, et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007;25(16):3111-14
   Google Scholar
• Chichester JA, Musiychuk K, Farrance CE, et al. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 2009;27(25-26):3471-4
   Google Scholar
• Mett V, Lyons J, Musiychuk K, et al. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 2007;25:3014-17
   PubMed Web of Science ®Google Scholar
• Mett V, Musiychuk K, Bi H, et al. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Respir Viruses 2008;2(1):33-40
   PubMed Web of Science ®Google Scholar
• Shoji Y, Chichester JA, Bi H, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008;26:2930-4
   PubMed Web of Science ®Google Scholar
• Shoji Y, Bi H, Musiychuk K, et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 2009a;27:1087-92
   PubMed Web of Science ®Google Scholar
• Shoji Y, Farrance CE, Bi H, et al. Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants. Vaccine 2009b;27(25-26):3467-70
   Google Scholar
• Shoji Y, Chichester JA, Jones M, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1and H5N1 influenza. Hum Vaccin 2011a;7(Suppl):41-5
   PubMed Web of Science ®Google Scholar
• Jones RM, Chichester JA, Mett V, et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS One 2013;8(11):e79538
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for national authorities on quality assurance for biological products. Annex 2. WHO Technical Report Series, No. 822. 1992
   Google Scholar
• Van der Laan JW, Minor P, Mahoney R, et al. WHO Informal Consultation Group. WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland 24–25 January 2005. Vaccine 2006;24:4271-8
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Guidance for Industry: drugs, biologics and medical devices derived from bioengineered plants for use in humans and animals. Draft Guidance. September 2002. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm124811.pdf [Last accessed on 30 May 2014]
   Google Scholar
• European Agency for the Evaluation of Medicinal Products. Guideline on the quality of biological active substances produced by stable transgene expression in higher plants. Draft 2. July 2006. Available from: www.triskel.com/4%20Guideline%20higher%20plants.pdf [Last accessed on 30 May 2014]
   Google Scholar
• Fischer R, Schillberg S, Hellwig S, et al. GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Adv 2012;30(2):434-9
   PubMed Web of Science ®Google Scholar
• Fischer R, Schillberg S, Buyel JF, Twyman RM. Commercial aspects of pharmaceutical protein production in plants. Curr Pharm Des 2013;19(31):5471-7
   Google Scholar
• Sigma-Aldrich. Available from: www.sigmaaldrich.com/safc/products/contract-manufacturing-solutions/therapeutic-proteins/native-sourced-extraction-and-purification.html) [Last accessed on 30 May 2014]
   Google Scholar
• Kentucky BioProcessing. Available from: www.kbpllc.com [Last accessed on 30 May 2014]
   Google Scholar
• Lai H, Chen Q. Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell Rep 2012;31(3):573-84
   PubMed Web of Science ®Google Scholar
• Bayer HealthCare. Available from: http://press.healthcare.bayer.com/en/press/news-details-page.php/13588) [Last accessed on 30 May 2014]
   Google Scholar
• Klimyuk V, Pogue G, Herz S, et al. Production of recombinant antigens and antibodies in Nicotiana benthamiana using ‘magnifection’ technology: GMP-compliant facilities for small- and large-scale manufacturing. Curr Top Microbiol Immunol 2014;375:127-54
   PubMed Web of Science ®Google Scholar
• Wirz H, Sauer-Budge AF, Briggs J, et al. Automated production of plant-based vaccines and pharmaceuticals. J Lab Autom 2012;17(6):449-57
   PubMedGoogle Scholar
• Fraunhofer USA Center for Molecular Biotechnology. Available from: http://fhcmb.org/ [Last accessed on 30 May 2014]
   Google Scholar
• Chichester JA, Jones RM, Green BJ, et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 2012;4(11):3227-44
   PubMed Web of Science ®Google Scholar
• Cummings JF, Guerrero ML, Moon JE, et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine 2014;32(19):2251-9
   PubMed Web of Science ®Google Scholar
• Pharmaceutical-technology. Fraunhofer Plant-Based Vaccine Factory, United States of America. Available from: www.pharmaceutical-technology.com/projects/fraunhofernewplantba/ Last accessed on 30 May 2014]
   Google Scholar
• Fraunhofer. Automated plant factory for the production of vaccines. Research News - Special Issue Jun 10, 2013. Available from: www.fraunhofer.de/en/press/research-news/2013/june/automated-plant-factory-for-the-prodution-of-vaccines.html [Last accessed on 30 May 2014]
   Google Scholar
• Icon Genetics. Company Profile. Available from: www.icongenetics.com/html/03.htm [Last accessed on 30 May 2014]
   Google Scholar
• Icon Genetics. Pilot plant for future-oriented technology opens in Halle. June 16, 2008. Available from: www.icongenetics.com/html/5948.htm [Last accessed on 30 May 2014]
   Google Scholar
• Icon Genetics. Icon Genetics successfully completes Phase I clinical study with personalized vaccines for treatment of non-Hodgkin’s lymphoma. Munich, January 31, 2014. Available from: www.icongenetics.com/html/5975.htm) [Last accessed on 30 May 2014]
   Google Scholar
• Rybicki EP. Third International Conference on Plant-Based Vaccines and Antibodies. Expert Rev Vaccines 2009;8:1151-5
   Google Scholar
• Fraunhofer Institute for Molecular Biology and Applied Ecology. Pharma-Planta: production of Clinical-grade API in Tobacco. Available from: www.ime.fraunhofer.de/en/businessareasMB/integrated_production_platforms/pharma-planta_productionofclinical-gradeapiintobacco.html [Last accessed on 30 May 2014]
   Google Scholar
• Pharmaceutical Processing. Caliber Recognized for Excellence In Technology. Available from: www.pharmpro.com/articles/2014/03/caliber-recognized-excellence-technology [Last accessed on 30 May 2014]
   Google Scholar
• Shepard S. Spotlight. Letter to the Editor. BioProcess Intern 2011;9(6):8-9
   Google Scholar
• The Business Journals. Medicago Successfully Completes the Production of More Than Ten Million Doses of H1N1 VLP Influenza Vaccine in One Month. Medicago Inc. Press Release. July 24. 2012. Available from: www.bizjournals.com/prnewswire/press_releases/2012/07/T0809 [Last accessed on 30 May 2014]
   Google Scholar
• The Business Journals. Medicago reports positive U.S. clinical trial results for its H1N1/seasonal influenza vaccine. Medicago Inc. Press Release. June 8, 2011. Available from: www.bizjournals.com/prnewswire/press_releases/2011/06/08/TO211 [Last accessed on 30 May 2014]
   Google Scholar
• Landry N, Ward BJ, Trépanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010;5(12):e15559
   PubMed Web of Science ®Google Scholar
• McKenna M. The Pandemic Vaccine Puzzle. A seven-part series on the chances for immunizing the world against pandemic flu. Minneapolis, MN: CIDRAP News, November 15. 2007. Available from: www.cidrap.umn.edu/news-perspective/2007/11/pandemic-vaccine-puzzle-seven-part-series-chances-immunizing-world-against#_Part_2:_Vaccine [Last accessed on 30 May 2014]
   Google Scholar
• Shoji Y, Farrance CE, Bautista J, et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respir Viruses 2012;6(3):204-10
   PubMed Web of Science ®Google Scholar
• Zhang S, Sherwood RW, Yang Y, et al. Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts. Proteomics 2012;12(8):1269-88
   PubMed Web of Science ®Google Scholar
• Study of the Safety and Immunogenicity of H1N1 Vaccine. Available from: http://clinicaltrials.gov/show/NCT01177202
   Google Scholar
• Wu J, Li W, Wang HQ, et al. A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis 2010;202(5):675-80
   PubMed Web of Science ®Google Scholar
• Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361(25):2414-23
   PubMed Web of Science ®Google Scholar
• Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults. Available from: http://clinicaltrials.gov/show/NCT01250795
   Google Scholar
• Wei CJ, Xu L, Kong WP, et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008;82(13):6200-8
   PubMed Web of Science ®Google Scholar
• Wilson IA, Cox NJ. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990;8:737-71
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Beirnaert E, Neirynck S, et al. Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells. Arch Virol 1996;141:1715-26
   PubMed Web of Science ®Google Scholar
• Kammerer RA, Kostrewa D, Progias P, et al. A conserved trimerization motif controls the topology of short coiled coils. Proc Natl Acad Sci USA 2005;102:13891-6
   PubMedGoogle Scholar
• Shoji Y, Jones RM, Mett V, et al. A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge. Hum Vaccin Immunother 2013;9(3):pii: 23234
   Google Scholar
• Deml L, Speth C, Dierich MP, et al. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005;42(2):259-77
   PubMed Web of Science ®Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006;40(1):60-5
   PubMed Web of Science ®Google Scholar
• Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007;6(3):381-90
   PubMed Web of Science ®Google Scholar
• Song JM, Hossain J, Yoo DG, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010;405(1):165-75
   PubMed Web of Science ®Google Scholar
• Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007;81(7):3514-24
   PubMed Web of Science ®Google Scholar
• McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007;358(2):334-46
   Google Scholar
• Kang SM, Yoo DG, Lipatov AS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009;4(3):e4667
   PubMed Web of Science ®Google Scholar
• Kang SM, Kim MC, Compans RW. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012;11(8):995-1007
   PubMed Web of Science ®Google Scholar
• Paliard X, Liu Y, Wagner R, et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum. Retroviruses 2000;16(3):273-82
   PubMed Web of Science ®Google Scholar
• Schirmbeck R, Böhm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996;39(1-2):111-19
   Google Scholar
• Win SJ, Ward VK, Dunbar PR, et al. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol 2011;89(6):681-8
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Zinkernagel RM, Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J Immunol 1998;161(11):5791-4
   Google Scholar
• Storni T, Lechner F, Erdmann I, et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002;168(6):2880-6
   Google Scholar
• Storni T, Ruedl C, Schwarz K, et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004;172(3):1777-85
   PubMed Web of Science ®Google Scholar
• Wang BZ, Quan FS, Kang SM, et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008;82(23):11813-23
   PubMed Web of Science ®Google Scholar
• Wang BZ, Xu R, Quan FS, et al. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 2010;5(11):e13972
   PubMed Web of Science ®Google Scholar
• Fiers W, De Filette M, El Bakkouri K, et al. M2e-based universal influenza A vaccine. Vaccine 2009;27(45):6280-3
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. ENGERIX®-B (Hepatitis B surface antigen [rys]). Prescribing Information. 2014
   Google Scholar
• Merck & Co., Inc. Recombivax HB® Hepatitis B Vaccine (Recombinant). Prescribing Information. 2014
   Google Scholar
• Merck & Co., Inc. GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] Prescribing Information. 2014
   Google Scholar
• GlaxoSmithKline. CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant]. Prescribing Information. 2014
   Google Scholar
• Khurana S, Wu J, Verma N, et al. H5N1virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011;85:10945-54
   PubMed Web of Science ®Google Scholar
• López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011;29(44):7826-34
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25(19):3871-8
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008;3(1):e1501
   PubMed Web of Science ®Google Scholar
• Mahmood K, Bright RA, Mytle N, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008;26(42):5393-9
   PubMed Web of Science ®Google Scholar
• Mumford RA, Barker I, Wood KR. The biology of the tospoviruses Ann. Appl. Biol 1996;128(1):159-83
   Google Scholar
• Taliansky M, Torrance L, Kalinina NO. Role of plant virus movement proteins. Methods Mol Biol 2008;451:33-54
   Google Scholar
• Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT00984945?term=medicago&rank=1 [Last accessed on 30 May 2014]
   Google Scholar
• Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT01302990?term=medicago&rank=5 [Last accessed on 30 May 2014]
   Google Scholar
• Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine. Available from: www.clinicaltrials.gov/ct2/show/NCT01244867?term=medicago&rank=3 [Last accessed on 30 May 2014]
   Google Scholar
• Ward BJ, Landry N, Trépanier S, et al. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine 2014;32(46):6098-106
   Google Scholar
• The Business Journals. Medicago reports positive Phase II final results for its avian flu pandemic vaccine. Medicago Inc. Press Release. June 30, 2011. Available from: www.bizjournals.com/prnewswire/press_releases/2011/06/30/TO669 [Last accessed on 30 May 2014]
   Google Scholar
• H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT01657929 [Last accessed on 30 May 2014]
   Google Scholar
• Infectious Disease Research Institute. IDRI and Medicago Report Positive Results for Phase I Clinical Trial for an H5N1 Vaccine. Press Release. April 17, 2013. Available from: www.idri.org/press-04-17-13.php [Last accessed on 30 May 2014]
   Google Scholar
• Landry N, Pillet S, Favre D, et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol 2014;154(2):164-77
   PubMed Web of Science ®Google Scholar
• Lico C, Mancini C, Italiani P, et al. Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. Vaccine 2009;27(37):5069-76
   PubMed Web of Science ®Google Scholar
• Meshcheriakova IuA, El’darov MA, Migunov AI, et al. Cowpea mosaic virus chimeric particles bearing ectodomain of matrix protein 2 (M2E) of influenza A virus: production and characteristics. Mol Biol (Mosk) 2009;43(4):741-50
   Google Scholar
• Matić S, Rinaldi R, Masenga V, Noris E. Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol 2011;11:106
   PubMed Web of Science ®Google Scholar
• Gilbert N. Europe prepares for drugs from GM plants. Nature 2009;460:791
   Google Scholar
• GlaxoSmithKline. FLUARIX (Influenza Virus Vaccine). Prescribing Information, 2013
   Google Scholar
• Sanofi Pasteur. Fluzone (Influenza Virus Vaccine). Prescribing Information, 2013
   Google Scholar
• United States Food and Drug Administration (FDA). FDA approves new seasonal influenza vaccine made using novel technology. News Release. January 16, 2013. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm [Last accessed on 02 June 2014]
   Google Scholar
• Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine. Available from: www.clinicaltrials.gov/ct2/show/NCT01991561?term=medicago&rank=2 [Last accessed on 30 May 2014]
   Google Scholar
• Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT01991587?term=medicago&rank=4 [Last accessed on 30 May 2014]
   Google Scholar
• Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults. Available from: http://clinicaltrials.gov/ct2/show/NCT02233816?term=medicago&rank=3 [Last accessed on 10 November 2014]
   Google Scholar
• Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like Particles (VLP) Quadrivalent Influenza Vaccine in the Elderly Population. Available from: http://clinicaltrials.gov/ct2/show/NCT02236052?term=medicago&rank=5 [Last accessed on 10 November 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Avian Influenza A (H7N9) Virus. Available from: www.cdc.gov/flu/avianflu/h7n9-virus.htm [Last accessed on 10 November 2014]
   Google Scholar
• PR Newswire. Medicago is First in the World to Report Positive Interim Results for its H7N9 Pre-Clinical Trial. Press Release. June 6. 2013. Available from: www.prnewswire.com/news-releases/medicago-is-first-in-the-world-to-report-positive-interim-results-for-its-h7n9-pre-clinical-trial-210378341.html [Last accessed on 10 November 2014]
   Google Scholar
• Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT02022163?term=nct02022163&rank=1 [Last accessed on 30 May 2014]
   Google Scholar
• Mortimer E, Maclean JM, Mbewana S, et al. Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol 2012;12:14
   Google Scholar